newsfilter
← Latest News
GlobeNewswire·

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026